Financing ·
On June 30, 2026, INmune Bio, Inc. entered into a warrant inducement offer letter and an amendment to common stock…
INMBInmune Bio, Inc.
On June 30, 2026, INmune Bio, Inc. entered into a warrant inducement offer letter and an amendment to common stock purchase warrants to extend maturity dates and induce holders to exercise 50% of their April 2024 Warrants at a reduced exercise price of $1.40 per share, down from $1.95. The company expects to receive approximately $905,957 in cash consideration for these exercises. INmune Bio, Inc. is a biotechnology company focused on developing immune-modulating therapies.